This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
113
APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Safety of APC8015F by Review of Reported Adverse Events
All subjects who received at least one infusion of APC8015F (N = 109) were included in the safety analysis set and were followed for safety. Refer to Serious Adverse Events and Other Adverse Events.
Time frame: periodically over 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UCLA
Los Angeles, California, United States
USC Keck School of Medicine
Los Angeles, California, United States
Sutter Cancer Center
Sacramento, California, United States
Kaiser Permanente Medical Group
San Diego, California, United States
Sharp HealthCare
San Diego, California, United States
UCSF Cancer Center
San Francisco, California, United States
Helen F. Graham Cancer Center
Newark, Delaware, United States
Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Walter Reid Army Medical Center
Washington D.C., District of Columbia, United States
Miami Cancer Center
Miami, Florida, United States
...and 48 more locations